Why This Matters for Your Career
Hikma is hiring 1 role related to this product
Company
Hikma
NJ - Berkeley Heights
External Resources
DRONABINOL by Hikma is cns, including central sympathomimetic activity. First approved in 2014.
Drug data last refreshed 13h ago
CNS, including central sympathomimetic activity. Cannabinoid receptors have been discovered in neural tissues. These receptors may play a role in mediating the effects of dronabinol.
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Dronabinol for Agitation in Dementia Crossover Trial
Dronabinol for Post-operative Pain After Lumbar Fusion
A RCT Comparing Dronabinol to a Placebo for Post-operative Pain in Total Joint Arthroplasty
Investigation of Cannabinoid Receptor Agonist Dronabinol in Patients With Functional Chest Pain
Study to Evaluate the Efficacy and Safety of Dronabinol Metered Dose Inhaler (MDI) in Acute Treatment of Migraine Headache
Worked on DRONABINOL at Hikma? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Hikma is hiring 1 role related to this product